Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Philipp

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
JAMA Dermatology|April 9, 2020
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical TrialAndrew Blauvelt, Craig L Leonardi, Melinda Gooderham, et al.
Journal of Molecular Medicine (Berlin, Germany)|March 31, 2009
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are notKerstin Wolk, Harald S Haugen, Wenfeng Xu, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 26, 2010
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"Alexander Nast, Matthias Augustin, Wolf-Henning Boehncke, et al.
Allergologie Select|January 11, 2021
Biologics for atopic diseases: Indication, side effect management, and new developmentsUta Jappe, Hendrik Beckert, Karl-Christian Bergmann, et al.
The Journal of Investigative Dermatology|May 20, 2015
Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European PatientsRotraut Mössner, Yvonne Frambach, Dagmar Wilsmann-Theis, et al.
The New England Journal of Medicine|April 20, 2017
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque PsoriasisKim A Papp, Andrew Blauvelt, Michael Bukhalo, et al.
The Journal of Investigative Dermatology|July 22, 2014
IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasisEllen Witte, Georgios Kokolakis, Katrin Witte, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 15, 2026
S1 Guideline: Therapy of generalized pustular psoriasisRotraut Mößner, Neda Cramer, Sascha Gerdes, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 21, 2021
Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und KomorbiditätAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 21, 2021
German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situationsAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
JAMA Dermatology|April 9, 2020
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical TrialAndrew Blauvelt, Craig L Leonardi, Melinda Gooderham, et al.
Journal of Molecular Medicine (Berlin, Germany)|March 31, 2009
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are notKerstin Wolk, Harald S Haugen, Wenfeng Xu, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 26, 2010
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"Alexander Nast, Matthias Augustin, Wolf-Henning Boehncke, et al.
Allergologie Select|January 11, 2021
Biologics for atopic diseases: Indication, side effect management, and new developmentsUta Jappe, Hendrik Beckert, Karl-Christian Bergmann, et al.
The Journal of Investigative Dermatology|May 20, 2015
Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European PatientsRotraut Mössner, Yvonne Frambach, Dagmar Wilsmann-Theis, et al.
The New England Journal of Medicine|April 20, 2017
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque PsoriasisKim A Papp, Andrew Blauvelt, Michael Bukhalo, et al.
The Journal of Investigative Dermatology|July 22, 2014
IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasisEllen Witte, Georgios Kokolakis, Katrin Witte, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 15, 2026
S1 Guideline: Therapy of generalized pustular psoriasisRotraut Mößner, Neda Cramer, Sascha Gerdes, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 21, 2021
Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und KomorbiditätAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 21, 2021
German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situationsAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
Pageof 7